Herpes Simplex Encephalitis: Lack of Clinical Benefit of Long-Term Valacyclovir Therapy.

Research output: Contribution to journalArticle

Abstract

Despite the proven efficacy of acyclovir therapy, herpes simplex encephalitis (HSE) continues to cause substantial morbidity and mortality. Among patients with HSE treated with acyclovir (ACV), the mortality rate is approximately 14-19%. Among survivors, 45-60% have neuropsychological sequelae at 1 year. Thus, improving therapeutic approaches to HSE remains a high priority.

Details

Authors
  • John W Gnann
  • Birgit Sköldenberg
  • John Hart
  • Elisabeth Aurelius
  • Marie Studahl
  • Britt-Marie Eriksson
  • Daniel Hanley
  • Fred Aoki
  • Alan C Jackson
  • Paul Griffiths
  • Lil Miedzinski
  • Diane Hanfelt-Goade
  • Daniel Hinthorn
  • Clas Ahlm
  • Allen Aksamit
  • Salvador Cruz-Flores
  • Ilet Dale
  • Gretchen Cloud
  • Penelope Jester
  • Richard J Whitley
Organisations
Research areas and keywords

Subject classification (UKÄ) – MANDATORY

  • Infectious Medicine
Original languageEnglish
Pages (from-to)683-691
JournalClinical Infectious Diseases
Volume61
Issue number5
Publication statusPublished - 2015
Publication categoryResearch
Peer-reviewedYes

Bibliographic note

The information about affiliations in this record was updated in December 2015. The record was previously connected to the following departments: Division of Infection Medicine (SUS) (013008000)